This is a study of GW642444M, a long-acting beta 2 specific agonist. This study will examine
GW642444M via the inhaled route and will assess the efficacy, safety, tolerability,
pharmacodynamics and pharmacokinetics of a single administration of three inhaled doses (25,
100 and 400 µg) of GW642444M in persistent asthmatics. This study will be a single-centre,
placebo-controlled, dose-ascending, five-way crossover in 30 asthmatic patients.
Key assessments: efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics will
be assessed by measurement of FEV1, blood pressure, pulse rate, 12-lead ECGs, clinical
laboratory safety tests, collection of adverse events and blood samples.